Glaucoma treatment. A review of people with primary open-angle glaucoma and ocular hypertension concluded that medical IOP lowering treatment slowed down the progression of visual field loss. Vascular flow and neurodegenerative theories of glaucomatous optic neuropathy have prompted studies on various neuroprotective therapeutic strategies, including nutritional compounds, some of which may be regarded by clinicians as safe for use now, while others are on trial. Intraocular pressure can be lowered with medication, usually eye drops. Several classes of medications are used to treat glaucoma, with several medications in each class. Each of these medicines may have local and systemic side effects.
Phacolytic glaucoma to as a ‘slit lamp examination’ of phacolytic glaucoma allows for specific identification of microcystic corneal edema and the presence of macrophages, white material (dotted with patches within the inside capsule of the lens) and intense flare and iridescent or hyper-refringent particles specific to phacolytic glaucoma. The time period which symptoms have been affecting the patient should be obtained as experiencing symptoms for a period longer than 5 days may result in further issues such as glaucomatous disc damage or poorer prognosis. Additionally, previous cataract or trauma surgery which have been conducted must be accounted for so that an accurate